Fig. 1. TP53 status does not affect osimertinib sensitivity of EGFR-mutated NSCLC cells.

a Immunoblot analysis of p53, p21, and total and phosphorylated (p) forms of EGFR, ERK, and AKT in PC9/p53^EV, PC9/p53^WT, and PC9/p53^MUT cells. β-actin was examined as a loading control. b Cell proliferation curves for PC9/p53^EV, PC9/p53^WT, and PC9/p53^MUT cells determined with a colorimetric assay. c Immunoblot analysis of EGFR signaling as well as of p53 and p21 in PC9/p53^EV, PC9/p53^WT, and PC9/p53^MUT cells treated with 100 nM osimertinib for 0, 6, 24, or 72 h. d Viability of PC9/p53^EV, PC9/p53^WT, and PC9/p53^MUT cells exposed to the indicated concentrations of osimertinib for 72 h as determined with a colorimetric assay. Data in (b) and (d) are means ± SEM of triplicates from one experiment and are representative of three independent experiments.